Navigation Links
Jefferson receives $1.7 million grant to study stem cells in intervertebral discs of the spine

(PHILADELPHIA) Scientists at Jefferson Medical College have received a five-year, $1.7 million National Institutes of Health grant funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases to study mechanisms regulating stem cell self-renewal and differentiation with the aim of regenerating diseased and painful intervertebral discs. A previous study by the same group showed that stem cells exist in both animal and human intervertebral discs. This grant will enable the researchers to continue studying the disc cells and determine factors which govern their activities in health and disease.

"Disc degeneration and the associated back pain that goes with it costs the U.S. healthcare industry approximately $100 billion annually," said Irving M. Shapiro, Ph.D., associate director of Orthopedic Research and the director of the Cell and Tissue Engineering Graduate Program at Jefferson Medical College of Thomas Jefferson

University. "As a major cause of lost productivity worldwide it is critical that we develop a treatment that will regenerate intervertebral disc structure and function."

A variety of factors contribute to the degeneration of the intervertebral disc including age, genetics and biomechanical factors. Several surgical procedures are available to pacify the pain associated with the degenerative disc, but the most common procedures often only provide symptomatic relief. No current therapy can completely restore the function of a degenerated disc nor prevent its further deterioration. Historically, investigations of the intervertebral disc have been limited in scope, leading to a lack of understanding of the biology and function of both healthy and diseased tissues.

"Researchers have tried repairing the discs by injecting them with agents that are thought to have beneficial effects on cell function," said Makarand Risbud, Ph.D, associate professor of Orthopedic Surgery at Jefferson Medical College of Thomas Jefferson University. "However, these treatments are limited in their effectiveness in restoring disc structure and function. Our ongoing studies suggest that a group of proteins that compromise the notch signaling pathway in the intervertebral discs are central to this process. These proteins regulate a variety of activities of stem cells including proliferation, self-renewal and differentiation. Our goal is to harness the body's own regenerative potential and activate endogenous cells."

Drs. Risbud and Shapiro are collaborating with Drs. Todd Albert and D. Greg Anderson, their clinical colleagues at the Rothman Institute at Jefferson, as well as Dr. Ernestina Schipani, an expert in molecular genetics at Harvard University. The investigators plan to develop a genetically engineered mouse model that lacks selected proteins of the notch signaling pathway in the intervertebral disc. This model will provide important mechanistic insights into the role of the notch signaling pathway in controlling disc cell activities.

"Eventually, we hope to be able to regulate the activities of the disc cells including fostering their inherent regenerative potential," said Risbud. "If we are able to do this it could lead to development of new therapies to treat degenerative disc disease providing relief to millions of back pain suffers."


Contact: Rick Cushman
Thomas Jefferson University

Related biology news :

1. Jefferson researcher awarded Landenberger Foundation grant for ALS research
2. Jefferson scientists discover a key protein regulator of inflammation and cell death
3. Jefferson Department of Surgery announces new pancreas tumor registry
4. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
5. Jefferson receives $11.6M NIH grant to study novel mechanisms of heart failure
6. Jefferson scientists studying the effects of high-dose vitamin C on non-Hodgkin lymphoma patients
7. Jefferson urologists studying regenerated neo-bladder to help spinal cord injury patients
8. Tulane receives grant to study limb regeneration
9. Springer Series editor John Smol receives two prestigious biology awards
10. URI receives $18 million grant to strengthen biomedical research capacity in Rhode Island
11. Vitamin D expert receives Linus Pauling Prize for Health Research
Post Your Comments:
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... ... on what they believe could be a new and helpful biomarker for malignant ... Click here to read it now. , Biomarkers are components in ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology: